Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a report released on Wednesday, June 18th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals' Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($0.97) EPS and FY2026 earnings at ($1.20) EPS.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.20.
Separately, Wall Street Zen lowered Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, June 6th.
Read Our Latest Analysis on Eledon Pharmaceuticals
Eledon Pharmaceuticals Stock Performance
Eledon Pharmaceuticals stock opened at $2.72 on Monday. The firm has a market capitalization of $162.87 million, a price-to-earnings ratio of -1.30 and a beta of -0.17. Eledon Pharmaceuticals has a fifty-two week low of $2.30 and a fifty-two week high of $5.54. The stock's fifty day moving average is $3.04 and its two-hundred day moving average is $3.69.
Institutional Trading of Eledon Pharmaceuticals
Several large investors have recently bought and sold shares of ELDN. Jane Street Group LLC purchased a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at $504,000. Point72 Asset Management L.P. purchased a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at $4,511,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at $101,000. Charles Schwab Investment Management Inc. lifted its position in shares of Eledon Pharmaceuticals by 100.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company's stock valued at $124,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at $490,000. Institutional investors and hedge funds own 56.77% of the company's stock.
About Eledon Pharmaceuticals
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
